Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
OptiNose
(NASDAQ:OPTN)
Intraday
$0.99
0.0647
[6.99%]
After-Hours
$0.99
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.99
0.0647
[6.99%]
At close: Apr 25
$0.99
0
[0.00%]
PreMarket: 7:49AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for OptiNose Stock (NASDAQ:OPTN)
OptiNose Stock (NASDAQ: OPTN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 25, 2024
Optinose Provides Corporate Updates; Expects To Produce Positive Income From Operations For Full Year 2025
Benzinga Newsdesk
-
37 minutes ago
Monday, April 22, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
2 days ago
Monday, March 18, 2024
Lake Street Maintains Buy on OptiNose, Raises Price Target to $4
Benzinga Newsdesk
-
Mar 18, 2024, 9:34AM
HC Wainwright & Co. Reiterates Buy on OptiNose, Maintains $5 Price Target
Benzinga Newsdesk
-
Mar 18, 2024, 6:58AM
Friday, March 15, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Mar 15, 2024, 5:33PM
OptiNose Shares Resume Trade
Happy Mohamed
-
Mar 15, 2024, 4:20PM
Trading Halt: Halt status updated at 4:15:00 PM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk
-
Mar 15, 2024, 4:15PM
Optinose Announces That FDA Approved XHANCE Nasal Spray For The Treatment Of Chronic Rhinosinusitis Without Nasal Polyps In Patients 18 Years Of Age And Older
Benzinga Newsdesk
-
Mar 15, 2024, 3:37PM
Trading Halt: Halted at 3:26:16 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
-
Mar 15, 2024, 3:26PM
Monday, March 11, 2024
HC Wainwright & Co. Initiates Coverage On OptiNose with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk
-
Mar 11, 2024, 7:12AM
Thursday, March 07, 2024
Optinose Reports Fourth Quarter And Full Year 2023 Xhance Net Revenue Of $19.9M And $71M
Benzinga Newsdesk
-
Mar 7, 2024, 7:06AM
OptiNose Q4 GAAP EPS $(0.09), Inline, Sales $19.86M Beat $19.23M Estimate
Benzinga Newsdesk
-
Mar 7, 2024, 7:05AM
Earnings Scheduled For March 7, 2024
Benzinga Insights
-
Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
OptiNose's Earnings: A Preview
Benzinga Insights
-
Mar 6, 2024, 2:01PM
Thursday, January 18, 2024
Optinose Announces The Publication Of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE In The Journal Of Allergy And Clinical Immunology: In Practice
Benzinga Newsdesk
-
Jan 18, 2024, 12:02PM
Wednesday, December 06, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Dec 6, 2023, 4:31PM
Gold Moves Higher; Campbell Soup Earnings Top Expectations
Lisa Levin
-
Dec 6, 2023, 2:45PM
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Dec 6, 2023, 2:43PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Dec 6, 2023, 12:31PM
Crude Oil Down 4%; Pharvaris Shares Spike Higher
Lisa Levin
-
Dec 6, 2023, 12:29PM
OptiNose shares are trading lower after the company announced that the FDA extended the review period for the supplemental new drug application of XHANCE by three months.
Benzinga Newsdesk
-
Dec 6, 2023, 11:57AM
US Stocks Higher; Private Payrolls Rise By 103,000 In November
Lisa Levin
-
Dec 6, 2023, 9:42AM
Why ENT-Focused OptiNose Shares Are Diving Today
Nabaparna Bhattacharya
-
Dec 6, 2023, 9:21AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Dec 6, 2023, 8:06AM
Optinose Reports 3-Month Extension Of FDA Review Period For Supplemental New Drug Application For XHANCE
Benzinga Newsdesk
-
Dec 6, 2023, 7:45AM
Thursday, November 09, 2023
OptiNose, Inc Expects FY23 XHANCE Net Revenues of $66.0M-$70.0M (Prior $64.0M-$70.0M)
Benzinga Newsdesk
-
Nov 9, 2023, 7:15AM
OptiNose Q3 EPS $(0.08) Vs $(0.18) YoY, Sales $19.82M Beat $18.68M Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 7:01AM
Earnings Scheduled For November 9, 2023
Benzinga Insights
-
Nov 9, 2023, 6:52AM
Monday, August 21, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
Benzinga Insights
-
Aug 21, 2023, 11:00AM
Lake Street Initiates Coverage On OptiNose with Buy Rating, Announces Price Target of $3
Benzinga Newsdesk
-
Aug 21, 2023, 9:15AM
Friday, August 11, 2023
Piper Sandler Maintains Overweight on OptiNose, Lowers Price Target to $3
Benzinga Newsdesk
-
Aug 11, 2023, 12:33PM
Thursday, August 10, 2023
OptiNose Expects FY23 XHANCE Net Revenues Of $64M-$70M (Prior View: $62M-$68M)
Benzinga Newsdesk
-
Aug 10, 2023, 7:18AM
OptiNose Q2 EPS $0.02 Beats $(0.11) Estimate, Sales $19.45M Beat $17.36M Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 7:03AM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Friday, July 28, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Jul 28, 2023, 5:32PM
Thursday, July 27, 2023
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue Of $19.5M
Bill Haddad
-
Jul 27, 2023, 7:10AM
Monday, July 10, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jul 10, 2023, 1:50PM
Wednesday, June 07, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Jun 7, 2023, 12:38PM
Tuesday, June 06, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Jun 6, 2023, 1:54PM
Wednesday, May 31, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
May 31, 2023, 1:04PM
Monday, May 22, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
May 22, 2023, 12:08PM
Friday, May 19, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
May 19, 2023, 1:59PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
May 19, 2023, 1:31PM
Thursday, May 11, 2023
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Optinose Expects XHANCE Net Revenues For 2023 Of $62.0M-$68.0M
Benzinga Newsdesk
-
May 11, 2023, 7:08AM
OptiNose Q1 EPS $(0.17) Vs. $(0.31) Last Year, Sales $11.85M Beat $9.95M Estimate
Benzinga Newsdesk
-
May 11, 2023, 7:06AM
Recap: OptiNose Q1 Earnings
Benzinga Insights
-
May 11, 2023, 7:05AM
Thursday, May 04, 2023
Optinose Announces FDA Acceptance Of Supplemental New Drug Application For XHANCE
Benzinga Newsdesk
-
May 4, 2023, 7:21AM
Thursday, March 09, 2023
OptiNose's Return On Capital Employed Insights
Benzinga Insights
-
Mar 9, 2023, 9:48AM
Tuesday, March 07, 2023
Optinose Expects FY23 XHANCE Net Revenues $62.0M-$68.0M, Q1 XHANCE Net Revenues $10.0M
Benzinga Newsdesk
-
Mar 7, 2023, 7:05AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch